Try our Advanced Search for more refined results
Life Sciences - September, 2015
290 articles
- Sanofi Vaccine Customers Get Class Cert. In Antitrust Case
- Class Cert. Denied Again In Ensure Drinkers' False Ad Suit
- 1st Circ. Gives Whistleblower Redo In Covidien FCA Suit
- Sandoz, UTC Settle Generic Remodulin Patent Suit
- Avon Beats Class Cert. Attempt In Anti-Aging Products Row
- Sirona Dental Investor Challenges $5.5B Sale To Dentsply
- Fed. Circ. Won't Rehear $15M Prosthetics Patent Suit
- Medtronic Escapes Investors' Claims Of Tainted Studies
- FTC Gives $3.3B Wright, Tornier Deal Conditional OK
- Hagens Berman To Appeal Sanctions In Thalidomide Litigation
- Deals Rumor Mill: Perrigo, Synaptics, Brown-Forman
- Nixon Peabody, Mintz Levin Can't Escape Malpractice Row
- Calif. Judge Tosses Invisalign False Ad Class Action
- Synergetics Investor Takes Aim At Valeant Deal
- A Look At The Legality Behind Daraprim's Price Spike
- Lessons From Key Players In Guidant MDL
- Approach To '2nd Medical Use' Claims Varies Across EU
- TriReme Medical Cleared In Catheter IP Trial, Attys Say
- Bass 'Patent Troll' Ally Seeks Help Targeting Depomed IP
- Abbott Wants Developmental Delays Kept From Depakote Trial
- Pelvic Mesh Users Slam Ethicon's Coaching Claims
- Pfizer Unit Pays $194M To End NJ Superfund Cleanup Row
- Hedge Fund Manager Again Targets Biogen's MS Drug Patent
- Corvus Pharma Raises $75M To Help Cancer Treatment R & D
- FDA Warning Wire: Workout Booster, Label Lies, Hemorrhoids
- Nexium Buyers Fight Drugmakers' Bid For Costs After Loss
- Feds Push Against Split Trial Over Meningitis Outbreak
- Fed. Circ. Affirms PTAB Finding In Cancer Drug Interference
- LifeScan May Be Why Patent Exhaustion Had No Pulse In Nero
- Pa. Jury Clears J&J Over Children's Motrin Claims
- Sen. Sanders Urges US To Back Drug Patent Exception
- Hawaii High Court Seeks Comments On Marijuana Ethics Rule
- Pa. Children's Motrin Case Heads To The Jury
- PTAB Decision Not To Sanction Bass Shifts Focus To Capitol
- A Cybersecurity Checklist For In-House Counsel
- Safe Harbor Protects Supplier Of Active Ingredient For ANDA
- Dinner Chat Doesn't Merit Inventor Credit In Patent Fight
- Judge Pares Humana's Claims In RICO Suit Against Medtronic
- Janssen Trims Two Claims From Remicade Biosimilar Battle
- Novartis Sclerosis Drug Patent Gets Axed In AIA Review
- Intervening Rights Defense Dooms Cancer Drug IP Claims
- AAI Backs Mylan's Appeal Of Doryx Product-Hopping Suit
- Sidley-Led Cytomx Seeks $106M IPO To Fund Cancer Drugs
- AbbVie Calls Docs Sought In Pay-For-Delay Suit Privileged
- SEC Charges 5 For Insider Trading On Gilead Acquisition
- Jury Awards Logtale $5M For IKOR's Investment Breach
- Steris-Synergy Merger Case — A Missed Opportunity
- Law360 Names Most Feared Plaintiffs Firms Of 2015
- Acacia Unit Settles Surgical Patent Suits With Zimmer
- PTAB Won't Sanction Bass For AIA Reviews Of Drug Patents
- Merck Fights To Toss Alaska AG's Suit Over Vioxx
- FDA Urged To Review More Data On Essure Side Effects
- Cardinal Health To Exit Antitrust Suit With $1.2M Deal
- 11 Firms To Guide Offerings Totaling $1.4B To End September
- 1st Circ. Told Warner Chilcott Paid Actavis To Kill Competition
- OPINION: Have Big Law Firms Lost Their Way?
- 6 IP Boutiques Punching Above Their Weight
- Bayer Didn't Violate FTC Supplements Settlement, Judge Rules
- Endo Sheds Drugs To Ease FTC Concerns Over $8B Par Buy
- $4.5M Wright Hip Implant Verdict Cut To $1M By Calif. Judge
- Hedge Fund Accused Of Extortion Loses AIA Review Bid
- IRS Urges Court To Uphold Mylan's $100M Tax Bill
- Strategies For Drug Cos. Facing Parallel Gov't Investigations
- Experts Say Ethicon Didn't Disclose Pelvic Mesh Dangers
- Kickstarting Information Governance: 3 Ideal Pilot Projects
- FTC Hits Fla. Weight-Loss Company With False Ad Suit
- FTC's Unusual Theory Made Steris Case An Uphill Battle
- Generics Maker Can't Duck Baxter Suit Over Brevibloc
- Biogen Can't Demand Royalties After Patent Expired, Suit Says
- Fed. Circ. Upholds Shire's Victory In Generic Vyvanse Suit
- 250 Philly Risperdal Suits May Be Time-Barred, Judge Says
- EPA Proposes Rule To Stop Pharmaceutical Flushing
- Nature's Way Slammed Over Move To Toss Ginkgo Pill Suit
- FTC Loses Bid To Block $1.9B Steris-Synergy Deal
- 10 Men Charged Over Steroid, Money Laundering Conspiracy
- 3rd Circ. Won't Rethink Lamictal Pay-For-Delay Ruling
- Perrigo Gets Claims Over CMS Drug Reimbursements Tossed
- Clinton Aims To Tackle Out-Of-Pocket Health Costs
- GSK Gets Wellbutrin Pay-For-Delay Antitrust Suit Nixed
- Actos Pay-For-Delay Class Action Gets The Boot
- Ethicon Says Pelvic Mesh Plaintiffs' Counsel Coached Doctors
- Senate Passes Bill To Increase Transparency In Gov't Deals
- AstraZeneca Hits Mylan With Patent Suit Over Cancer Generic
- DLA Piper Doubles Hamburg Office With Bird & Bird Raid
- Takeda Manipulated Gout Drug Clinical Trial, FCA Suit Claims
- Stock Tipper Can't Nix SEC Settlement After Newman
- FDA Regulation Catches Up To Next-Gen Gene Sequencing
- FDA Says Essure Birth Control Complaints Have Spiked
- Mylan Countersues Perrigo Over $27B Hostile Takeover Bid
- J&J's Ethicon Unit Defends Pelvic Mesh In Dallas Trial
- Ethicon Mounts 4th Circ. Appeal Of $3M Pelvic Mesh Verdict
- Medicare Group Opposes Carveout For Drug Patents
- Costco Urges Court To Toss Generic Lipitor Labeling Suit
- Aggrenox Buyers Blast Discovery Bid In Antitrust MDL
- FDA Warning Wire: Rust, Cancer Risks, Trial Dangers
- Horizon Pharma Seeks To Block IGI's Pennsaid Generic
- J&J Fights Class Cert. In 'Natural' Baby Wash False Ad Row
- 2nd Circ. Shows Difficulties Robinson-Patman Claims Face
- The 4 Firms In-House Counsel Fear The Most
- Supplement Maker Says Nutrex Is Infringing Trademark
- Mylan Takes Benicar Patent Dispute To The Supreme Court
- Don't Miss It: Hot IPOs & Firms We're Following
- Bayer CropScience Reaches $5.6M Deal Over Plant Explosion
- Mylan To Nix Anti-Takeover Tool Used Against Teva
- Investors Slam Valeant's Bid To Duck Insider Trading Suit
- SEC Says Stem Cell Research Co. Execs Misled Investors
- Vinson & Elkins Nabs 2 IP Pros From Perkins Coie
- Bayer Sues Drug Info Co. For Posting False Mirena Price
- Amgen Sues Hospira Over Biosimilar Info, Notice
- Stryker Slams Attys' Fee Bid In $6.8M TCPA Class Action Deal
- Lawmakers Want Indian IP, Food Barriers Curtailed In Summit
- The FDA's Risk-Based Approach To Medical App Enforcement
- 3rd Circ. Urged To Revive Avandia Suit Against GSK
- Boston Scientific Says Plaintiff Trying To Reopen Discovery
- Arthrex Asks High Court To Weigh Obviousness Review
- Pfizer, FDA Updating Pregnancy Caution On Zoloft Label
- Plaintiff With Dark Past Drops Boston Scientific Mesh Suit
- CORRECTED: Lenox's Counsel Sanctioned In Medtronic Antitrust Row
- J&J Pelvic Device Gets 1st Court Test In Dallas Trial
- U. of Colo. Says Amgen Withholding Arthritis Med Royalties
- Bard, Whistleblower Agree To End Catheter FCA Suit
- 5th Circ. Upholds VA Med Malpractice Judgment For Widow
- Luitpold Entitled To Some Damages In $120M Contract Dispute
- Provigil Buyers Want $141M In Fees For Cephalon Deal
- Calif. Jury Clears Hyland's In $255M False Ad Trial
- Real Estate Rumors: Moody's, Aduro Biotech, Brookhill
- A Possible Regulatory Reboot For US Biotech
- 2nd Circ. Stays Recall Of Pregnancy Tests In False Ad Row
- Hyland's 'Sugar Pill' False Ad Trial Wraps With $255M Ask
- Gatorade Owner No Fan Of 'Haterade,' Sues Creator Over TM
- Medtronic Infuse Injury Plaintiff Takes Appeal To Top Court
- Fixodent Users Try To Revive Zinc Sickness MDL Against P&G
- Insurance Co. Claims Limited Liability In Bard Pelvic Mesh Row
- Pa. Judge Trims Claims In Ex-Teva Atty's Wrongful Firing Suit
- Gilead Sues Lupin Over Plans To Produce Generic Tamiflu
- 4 Takeaways From FDA's Biosimilars Briefing
- Real Estate Rumors: Goldman, Jabal Omar, Baxalta
- Perrigo Rejects Mylan Offer Again, Files Suit
- China's Biostime Buys Into $1.2B Australian Vitamin Maker
- GeneDx Says Rival Startup Poaches Staff For Trade Secrets
- FTC Slams Supplement Co. Recusal Bid In Labeling Suit
- Crafting Method Of Treatment Claims To Avoid Multiple Actors
- Ex. Pfizer Co. Beats Much Of Defective Poultry Vaccine Suit
- Nutraceutical's Homeopathics Just 'Sugar Pills,' Suit Says
- O'Melveny & Myers Nabs Life Sciences Co-Head
- J&J Unit Wants $1.2M Pelvic Mesh Judgment Wiped Out
- Sens. Urged To Unveil Painkiller Probe Of Purdue, J&J, Endo
- Cooley Snags Ex-WilmerHale Team In London
- Amgen Inks $300M Deal For Dutch Drugmaker
- UAE Investors Dodge SEC's $3.7M Insider Trading Suit
- Otsuka Hits Hetero With Patent Suit Over Generic Diuretic
- Dentsply Buying Rival Sirona For $5.5B In Dental Co. Merger
- Provigil Buyers Again Say Class Cert. Order Needs Tweaking
- Obama Taps FDA Deputy Commissioner To Lead Agency
- Lupin Pushes 4th Circ. To Block Alaska AG's Info Demands
- Meningitis Outbreak Worker Seeks Split From Murder Case
- Allergan Fights To Keep IPR Extortion Fight In Federal Court
- Cooley-Led Seattle Genetics Nets $552M In Follow-On
- Allergan Seeks To Block Pfizer Unit's Generic Dry-Eye Drug
- FDA Warning Wire: Pigeons Invade Pharma Plant
- Sens. Float 2 Bills To Crack Down On Pay-For-Delay Deals
- Solving Law Firm Staffing Problems Through Innovation
- Pregnancy Test Maker Denies False Ad Campaign In 2nd Circ.
- Takeda Says Most Actos Claimants Want In On $2.4B Deal
- FDA Panel Backs Collegium's 'Abuse-Deterrent' Painkiller
- Drug Supplier Hits VA With Suit Over Potential Debarment
- Insurer Says Mass. High Court Needn't Hear Atty Conflict Row
- Wyeth Says Medicaid Didn't Trigger Protonix Discounts
- Depomed Urges Stockholders To Snub Latest Horizon Offer
- DLA Piper Adds Ex-Finnegan IP Managing Partner In Boston
- FDA Slashes Forecast On Alerts For Counterfeit Drugs
- 'No Basis In Law' For FDA Pill Size Limits, Group Says
- Rival Must Pay For Infringing AngioScore Cath IP, Jury Told
- Possible Effects Of Mass. Nonresident Pharmacy Licensure
- GSK False Ad Suit Over Teva's Generic Wellbutrin Frozen
- Goodwin-Led Dimension Therapeutics Preps $115M Debut
- Adderall Buyers Slam Drugmaker's Class Cert. Objections
- US Endoscopy Gets PTAB To Nix CDX Biopsy Brush Patent
- Olympus Hit With 3rd Pa. Suit Claiming Device Spread Cancer
- Covidien Investor Lambasts Deal Over $43B Medtronic Merger
- Baker Botts Adds Trio Of IP Partners From Vinson & Elkins
- Amgen Heads To High Court Over Handling Of Worker Stock
- Daiichi Asks Justices To Settle Fight Over Disclaimed Drug IP
- Celgene Calls Kyle Bass' AIA Review Bids 'Harassment'
- Biotech Co. Cellceutix Hyped Sham Drugs, Class Action Says
- 3 Life Sciences Cos. Set To Price IPOs After Long Market Lull
- Husch Blackwell Snags Ex-Leydig Voit IP Atty
- SIGA Seeks Another Extension Of Ch. 11 Exclusivity Period
- Drugmakers Have Tough Task In Quest For AIA Exemption
- Mylan, Ranbaxy Slam Bid To Change Provigil Class Cert.
- J&J, Bayer Sued For Downplaying Risks Of Xarelto
- Kansas City Fed Says Pot Credit Union Can't Have Account
- FDA Nixes Bid For 'Special Flexibility' For Orphan Drugs
- Barnes & Thornburg Adds Trial Atty From Greenberg Traurig
- Pfizer Loses Lyrica Patent Fight In UK Court
- Ex-Harvard Doc Defends Hyland's In $350M False Ad Trial
- AbbVie, Besins Told To Give Judge Disputed Docs In FTC Fight
- FDA Strengthens Warning For Type 2 Diabetes Meds
- Diet Supplement Co.'s Ex-Owner Headed To Prison For Fraud
- Allergan Allows Amneal To Market Generic Namenda In 2020
- King & Spalding Lures Off-Label Expert From FDA
- Prograf Maker Says Class Cert. Doesn't Clear 1st Circ.'s Bar
- Reckitt Launches Counterclaims In Mucinex Antitrust Suit
- Litigation Financing May Ease Your Year-End Cash Crunch
- SEC Settles Insider-Trading Charges Over GE Deal
- Whole Foods Customers Ready To Drop Homeopathy Claims
- Amgen, Sandoz Duel Over En Banc Bids In Biosimilars Fight
- NJ Benicar Side-Effect Suits Combined In Atlantic County
- USTR Seeks Data On 'Notorious' IP Infringement Markets
- Which Cos. Are Most Likely To Benefit From Innovation Box?
- Children's Motrin Didn't Cause Skin Condition, Pa. Jury Hears
- Morgan Lewis Adds Ex-Teva Counsel As White Collar Partner
- FDA's Primary Weapon In Food Fights: Warning Letters
- Pacira Sues FDA Over Constraints On Pain Drug's Marketing
- Thermo Fisher Sanctioned Over Flubbed Depo In Fraud Suit
- FDA Warning Wire: 'Adulterated' Devices, 'Modified' Tobacco
- 9th Circ. Axes Ex-InterMune CEO's Suit Over Conviction News
- Baker & McKenzie Adds Partners And Counsel In Miami, DC
- House Passes E-Warranty Bill, Renews Health Programs
- SEC Affirms Bar On CPA Charged With Leaking Sanofi Deal
- J&J Blasted Over Children's Motrin Warning At Trial Kickoff
- LifeCell Sues To Escape LifeNet Graft Patent Threat
- Fed. Circ. Nixes Ivera Loss In Disinfectant Cap Patent Case
- FTC Says AbbVie Can't Shield Docs In Pay-For-Delay Fight
- Cymbalta Plaintiffs To Appeal To 9th Circ. After Trial Losses
- Stryker Asks Judge To OK $6.8M TCPA Class Action Deal
- Pharma Reps Slam PTAB Over 'Skewed' Procedural Rules
- Mylan To Take Proposal Directly To Perrigo Shareholders
- 5th Circ. Kicks Stryker Foot Implant Suit To State Court
- 3 Life Sciences Cos. Polish $300M In Anticipated Floats
- Concordia's $3.5B Deal Grows Rare Disease Drug Portfolio
- Legal Vs. Illegal Drugs In Event Cancellation Policies
- Hyland's Sells Placebos, Doctor Says In $350M False Ad Trial
- Genzyme Seprafilm Admissions Muted In New DOJ Settlement
- FTC Says It Has Evidence To Block $2B Steris-Synergy Deal
- Sanofi Pays $2.4M To Kill Cancer Drug Sales Class Action
- Texas Justices Again Stay Out Of Fen-Phen Referral Fee Fight
- Malpractice Challenge In $50M Eli Lilly Settlement Stands
- Artificial Joint Co. Hid Issues Before $121M IPO, Suit Claims
- Impax Board Dodges Suit Over Bugs In Its Drugs, For Now
- Past Defeats Bode Ill For J&J In Pa. Children's Motrin Trial
- 6th Circ. Told Ethicon Surgical Stapler Suit Belongs In US
- GSK Tells 3rd Circ. To Uphold Dismissal Of Avandia Suit
- Inside The Summer's Hottest M&A Plays
- Allergan To Pay $300M For Glaucoma Treatment Developer
- EPA's Hazardous Waste Rule Is Just What The Doctor Ordered
- Hyland's Faces Disappointed Mom In $350M False Ad Trial
- Motrin Plaintiffs Say Bartlett Doesn't Block All Defect Claims
- GSK Fights To Block Expert For Reed Smith Atty's Widow
- Despite Denial, Bass Launches New Attack On Acorda Patents
- Bass Blasts Sanctions Bid, Says Drug AIA Reviews Aid Public
- Genzyme Pays $32.5M Criminal Fine For Seprafilm Marketing
- Judge Rejects $3M CVS Wage Settlement With Pharmacists
- Avalanche, Investors Ask To Consolidate Stock Drop Suits
- VisionAid Asks Mass. High Court About Atty Conflict Claim
- J&J Unit Can't Get Judge To Reconsider Bid To Nix TCPA Suit
- Sandoz Launches First Biosimilar At 15% Discount
- Brinks Gilson Adds Womble Carlyle, Katten Muchin Attys
- TIG Asks 6th Circ. To Nix $9M Stryker Knee Ruling
- 340B Omnibus Guidance Could Lead To Increased Drug Costs
- Homeopathic Co. CEO Defends Testing At $350M False Ad Trial
- Supreme Court Lifts Stay On Akebia, FibroGen Patent Fight
- Female Workers Win Conditional Cert In $100M Sex-Bias Row
- Trial Wins Boost Eli Lilly In Cymbalta Cases As MDL Bid Looms
- 1st Circ. Ruling Doesn't Apply In Labeling Suit, CVS Says
- Debevoise, Fox Rothschild Rep Lannett In $1.2B Drug Co. Buy
- Mass. Judge Says Pfizer Whistleblower Suit Likely To Proceed
- Pharmacia Shakes Schools' Toxic Light Ballasts Suit
- Real Estate Rumors: Gilead Sciences, Starwood, TGM
- PTAB Denies Hedge Fund's Bid For Biogen Patent Review
- Abbott, AbbVie Lied To Court In Depakote Suit, Plaintiff Says
- 2nd Circ. Stays Recall Of Misleading Swiss Pregnancy Tests
- Amgen Can't Block Sandoz Biosimilar At Fed. Circ.
- Skadden-Led Valeant Inks Deal For Surgical Device Maker
- Patent Invalidity Rates: The Summertime Blues Continue
- The Tension Between Corporate Opportunity And Innovation
- PTAB Misconduct Rule Won't Deter Hedge Fund Attacks
- Feds Tells 9th Circ. Ex-Oriole Can't Block Trading Evidence
- Supreme Court Halts Discovery In Anemia Drug Patent Suit
- FDA Warning Wire: Powdered Caffeine, Kim Kardashian
- Plaintiffs Fight 3rd Bid To Toss Protein Powder Ad Suit
- Judge Urged To Ax 'Tortured' Zoloft Birth Defect Testimony
- Merck Beats Back Whistleblower's FCA Claims Over Integrilin
- Claims, Experts Cut From Hip Implant Bellwether Case
- PTAB To Scrutinize Hedge Fund's Use Of AIA Review Program
- Eli Lilly Cleared By Jury In Cymbalta Withdrawal Suit
- Eisai Says FDA Wrongly Denied Drug Exclusivity Extension
- Zimmer Calls Knee Implant MDL Trial Plan A Waste Of Time
- J&J Says Cherokees' Risperdal Suit Should Stay Federal
- How Sequenom Lost Patent Protection For Fetal DNA Test